26 stories found
Samsung Biologics has published a prospectus for a public tender offer to acquire Danish biotechnology company PolyPeptide Group, with the formal takeover bid expected to launch in September. The move expands Samsung's capabilities in peptide synthesis and contract manufacturing services.
South Korean giant Samsung Biologics plans to acquire Baar-based Swiss peptide manufacturer Polypeptide, signaling ambitious growth plans by Asian companies in the production of pharmaceuticals.
Samsung Biologics is intensifying its research and development to strengthen its position in the contract development and manufacturing organization market, utilizing proprietary platforms and next-generation modalities.
Unionized workers at Samsung Biologics returned to work after a five-day walkout but decided to continue negotiations with the company under a work-to-rule campaign.
The labor union and management at Samsung Biologics are scheduled to resume negotiations on Monday, following the company's first-ever strikes in its 15-year history. These talks aim to resolve ongoing labor disputes.
The union at Samsung Biologics has launched its first-ever general strike, citing an ongoing dispute over pay and working conditions.
Samsung Biologics has officially acquired a biopharmaceutical manufacturing plant in Rockville, Maryland, marking its first production foothold in the United States, following its announced acquisition of a U.S. facility from GSK for US$280 million.
Samsung Biologics announced the launch of in-house master cell bank production and vector construction services, aiming to enhance its contract development organization capabilities and accelerate drug development.
Samsung Biologics, Eli Lilly to establish biotech incubator in Incheon Yonhap News Agency
Samsung Biologics intends to raise approximately 3 trillion won through a rights offering to finance its proposed acquisition of peptide maker PolyPeptide Group. The capital injection will support the company’s broader expansion strategy in the contract development and manufacturing sector.
Samsung Biologics has announced its acquisition of Swiss peptide manufacturer PolyPeptide Group in an all-cash deal valued at $1.81 billion. This strategic move expands Samsung Biologics' presence into the peptide market.
Samsung Biologics, a leading Korean contract development and manufacturing organization, is set to establish its first official European sales office in Amsterdam as part of its global expansion strategy.
A five-day strike at Samsung Biologics is transitioning to a work-to-rule phase as negotiations between labor and management remain deadlocked, marking the first such action in 15 years.
Unionized workers at Samsung Biologics, the biotech arm of Samsung Group, continued their strike for a second day, as negotiations over wages and other issues remain unresolved.
The union at Samsung Biologics has initiated its first-ever general strike, stemming from an ongoing dispute over pay. This industrial action marks a significant escalation in labor relations at the company.
Unionized workers at Samsung Biologics Co. have voted in favor of going on strike to demand higher wages in ongoing negotiations.
Samsung Biologics has highlighted its contract development and manufacturing organization, or CDMO, capabilities at Biologics Manufacturing Asia 2026 in Singapore, receiving a bioprocessing excellence award during the two-day event. According to Samsung Biologics on Thursday, the Korean CDMO leader presented its top-notch CDO technologies and services at the conference on Wednesday. Lim Heon-chang, director of formulation development at Samsung Biologics’ CDO division, introduced case studies of
Samsung Biologics and Eli Lilly are partnering to establish a biotech incubator in Incheon, South Korea.
Samsung Biologics is implementing a strategy of geographic diversification, which is described as a sound business decision. This move aims to expand the company's market reach and mitigate risks associated with reliance on a single region.
The labor union at Samsung Biologics has voted to separate from the Samsung Group-wide super-enterprise union, opting for an independent company-level structure amidst stalled wage negotiations.
South Korea's leading biopharmaceutical firms, Samsung Biologics and Celltrion, are facing unprecedented labor disputes between their unions and management despite strong earnings.
The strike by unionized workers at Samsung Biologics has entered its fifth day, with negotiations to resolve the industrial action reportedly stalled. The company estimates losses exceeding $100 million due to the ongoing walkout, as workers demand higher wages and expanded performance-based compensation.
The union at Samsung Biologics has initiated its first general strike, protesting an ongoing dispute regarding pay and working conditions.
Samsung Biologics' growth outlook is uncertain as a potential first-ever strike by its labor union raises risks to production and client trust, with the union demanding a 14 percent wage increase and a significant cash payout.
Samsung Biologics has been recognized for its advancements in sustainability at the 2026 CDMO Leadership Awards, highlighting its commitment to environmental and social responsibility.
Samsung Biologics has partnered with Eli Lilly to establish an open innovation hub for emerging biotechnology companies in Korea, marking Eli Lilly's first such site outside the United States and China.